SARS-CoV-2 neutralizing antibodies after first vaccination dose in breast cancer patients receiving CDK4/6 inhibitors

Undoubtedly, the development of COVID-19 vaccines displays a critical step towards ending this devastating pandemic, considering their protective benefits in the general population. Yet, data regarding their efficacy and safety in cancer patients are limited. Herein we provide the initial analysis o...

Descripción completa

Detalles Bibliográficos
Autores principales: Zagouri, Flora, Terpos, Evangelos, Fiste, Oraianthi, Liontos, Michalis, Briasoulis, Alexandros, Katsiana, Ioanna, Skafida, Efi, Markellos, Christos, Kunadis, Elena, Andrikopoulou, Angeliki, Kaparelou, Maria, Koutsoukos, Konstantinos, Gavriatopoulou, Maria, Kastritis, Efstathios, Trougakos, Ioannis P., Dimopoulos, Meletios-Athanasios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Short Communication
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8402928/
https://www.ncbi.nlm.nih.gov/pubmed/34481366
http://dx.doi.org/10.1016/j.breast.2021.08.017
Descripción
Sumario:Undoubtedly, the development of COVID-19 vaccines displays a critical step towards ending this devastating pandemic, considering their protective benefits in the general population. Yet, data regarding their efficacy and safety in cancer patients are limited. Herein we provide the initial analysis of immune responses after the first dose of vaccination in 21 breast cancer patients receiving cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors. The levels of neutralizing antibodies post vaccination were similar to the matched healthy controls, whereas no safety issues have been raised. Further exploration is needed to reduce the uncertainty of SARS-CoV-2 immunity among cancer patients under treatment.

Ejemplares similares